docj Sunday, 02/09/20 12:40:59 PM Re: Jimmy Joe
Post# of 36566
(Total Views: 483)
Posted On: 02/09/2020 12:44:46 PM
docj Sunday, 02/09/20 12:40:59 PM
Re: Jimmy Joe post# 10890 0
Post #
10891
of 10891
Jimmy Joe Sunday, 02/09/20 12:01:41 PM
Re: None 0
Post #
10890
of 10890
Quote:
February 6, 2020 - Generex Biotechnology announced that the company is working with third-party groups and government agencies to reactivate the previously robust research and development to generate Ii-Key peptide vaccines against pandemic viruses. The patented NuGenerex Immuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that is chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation.
"Of all the companies mention I didn't think Generex would be among them.
Interesting."
Hey JJ, I think your comment reveals an important point. Generex has been consumed for the past year or more on it's acquisition strategy as well as up listing and NGIO spin out. While these steps are huge for Generex's growth strategy, a high cost has been paid in "newer" investors ignorance of what Generex has accomplished prior to rising from the dead. I believe they are beginning to fix that with the video interviews they've been doing. I believe investors would benefit, as would Generex in the long run, if past accomplishments were highlighted via some type of timeline summary of who, what, when and where. I would wager a few of my GNBT shares a large number of current investors had no idea AE/Generex had studied influenza and novel flu's like avian, swine and such.
Generex would do well to redo the website and provide at least some detail about every company they have under the umbrella, their history and current happenings, along with partner companies and the like.
What Generex has done, survived through and plans to do in the near future has not gained the attention it deserves.
docj
Re: Jimmy Joe post# 10890 0
Post #
10891
of 10891
Jimmy Joe Sunday, 02/09/20 12:01:41 PM
Re: None 0
Post #
10890
of 10890
Quote:
February 6, 2020 - Generex Biotechnology announced that the company is working with third-party groups and government agencies to reactivate the previously robust research and development to generate Ii-Key peptide vaccines against pandemic viruses. The patented NuGenerex Immuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that is chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation.
"Of all the companies mention I didn't think Generex would be among them.
Interesting."
Hey JJ, I think your comment reveals an important point. Generex has been consumed for the past year or more on it's acquisition strategy as well as up listing and NGIO spin out. While these steps are huge for Generex's growth strategy, a high cost has been paid in "newer" investors ignorance of what Generex has accomplished prior to rising from the dead. I believe they are beginning to fix that with the video interviews they've been doing. I believe investors would benefit, as would Generex in the long run, if past accomplishments were highlighted via some type of timeline summary of who, what, when and where. I would wager a few of my GNBT shares a large number of current investors had no idea AE/Generex had studied influenza and novel flu's like avian, swine and such.
Generex would do well to redo the website and provide at least some detail about every company they have under the umbrella, their history and current happenings, along with partner companies and the like.
What Generex has done, survived through and plans to do in the near future has not gained the attention it deserves.
docj
(2)
(0)